REG - Creo Medical Group - Change of Nominated Adviser and Joint Broker

Creo MedicalAnnouncement

16/10/2023 10:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231016:nRSP2396Qa&default-theme=true

RNS Number : 2396Q  Creo Medical Group PLC  16 October 2023

 

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Change of Nominated Adviser and Joint Broker

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the
emerging field of surgical endoscopy, announces that following the completion
of the all share merger between Cavendish Securities plc (previously named
Cenkos Securities plc) and Cavendish Financial plc (previously named finnCap
Group plc), as a consequence of internal reorganisation within the Cavendish
Group, the Company has changed its Nominated Adviser and Joint Broker from
Cavendish Securities plc to Cavendish Capital Markets Limited.

 

Enquiries:

 

 Creo Medical Group plc                            www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                +44 (0)1291 606 005

 Cavendish Capital Markets Limited                 +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson (Sales)

 Numis Securities Limited (Joint Broker)           +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Euan Brown

 Walbrook PR Ltd                                   Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen                          Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

 Phillip Marriage                                  +44 (0)7867 984 082

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPFFLSUMEDSEFS